Julia Rotow, MD, of Dana-Farber Cancer Institute, and Ticiana Leal, MD, of Winship Cancer Institute of Emory University, discuss how they evaluate and treat patients with EGFR-mutant non–small cell lung cancer who progress on first-line osimertinib, including rebiopsy, local therapy, the phase 3 SAFFRON data for osimertinib plus savolitinib in MET-driven resistance, and all-comer options such as antibody-drug conjugates, and how they view the first-line and later-line landscape for EGFR exon 20 insertion–mutated disease after the PAPILLON, WU-KONG28, REZILIENT3, and FURVENT trials.
Julia Rotow, MD, of Dana-Farber Cancer Institute, opens this OncLive Insights discussion on EGFR-mutant non–small cell lung cancer with Ticiana Leal, MD, of Winship Cancer Institute of Emory University, by asking what progression on first-line osimertinib looks like in clinic.
Julia Rotow, MD, of Dana-Farber Cancer Institute, asks Ticiana Leal, MD, of Winship Cancer Institute of Emory University, how she uses local therapy for oligoprogression or consolidation in EGFR-mutant non–small cell lung cancer.
